RecruitingNot ApplicableNCT06422455

Access to Genetic Testing in Underserved Patients With Cancer

Increasing Access to Genetic Testing in Underserved Patients Using a Multilingual Conversational Agent


Sponsor

University of Southern California

Enrollment

800 participants

Start Date

Oct 24, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider. Patients with cancer are increasingly recommended for genetic testing as standard of care. Multiple factors contribute to low usage of genetic testing but for many patients the lack of access to genetic counseling and testing is an important and flexible factor. Lack of access is especially relevant to racial/ethnic minority patients and those living in non-metropolitan rural settings who are frequently cared for at safety-net hospitals with limited genetics services. Alternative delivery models are necessary to improve rates of access to genetic testing in patients with cancer. Health information technology is under used by genetics providers. A patient-facing relational agent (PERLA) will provide pre-test genetics education in both English and Spanish across two clinical settings to facilitate more timely access to genetic testing. Using the PERLA intervention may help researchers learn different ways to provide education about genetic testing to patients with cancer compared to usual care.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is helping underserved patients with certain cancers access genetic testing to find out if they carry hereditary gene mutations (like BRCA1/2) that could affect their treatment choices and help their family members know their own risk. **You may be eligible if...** - You are 18 or older and can read/write in English or Spanish - You have been diagnosed with one of: ovarian cancer, pancreatic cancer, high-risk prostate cancer, breast cancer at or before 50, bilateral breast cancer, triple-negative breast cancer, or male breast cancer - OR you are a healthcare provider treating patients with any of these cancers - You can give informed consent **You may NOT be eligible if...** - You cannot see, read, or write - You cannot give informed consent - You do not speak English or Spanish - You do not have one of the listed cancer types Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBest Practice

Receive provider-based genetic counseling

OTHEREducational Intervention

Receive genetics education

OTHERElectronic Health Record Review

Ancillary studies

OTHERGenetic Counseling

Receive provider-based genetic counseling

OTHERInterview

Ancillary studies

OTHERSurvey Administration

Ancillary studies


Locations(2)

USC / Norris Comprehensive Cancer Center

Los Angeles, California, United States

University of Rochester

Rochester, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06422455


Related Trials